Seven Eight Capital, LP Protagonist Therapeutics, Inc Transaction History

Seven Eight Capital, LP

  • $1.05 Billion
  • Q3 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 12, 2024
BUY
$24.66 - $34.8 $735,114 - $1.04 Million
29,810 Added 426.89%
36,793 $1.27 Million
Q1 2024

May 13, 2024
BUY
$21.79 - $32.15 $152,159 - $224,503
6,983 New
6,983 $202,000
Q2 2023

Aug 14, 2023
BUY
$18.02 - $29.36 $488,197 - $795,421
27,092 New
27,092 $748,000

Others Institutions Holding PTGX

# of Institutions
247
Shares Held
56.4M
Call Options Held
76.3K
Put Options Held
114K
View Full List

About Protagonist Therapeutics, Inc

PTGX Quotes by TradingView
  • Ticker PTGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,084,100
  • Market Cap $1.92B
  • Description
  • Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...
More about PTGX
Track This Portfolio

Track Seven Eight Capital, LP Portfolio

Follow Seven Eight Capital, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Seven Eight Capital, LP, based on Form 13F filings with the SEC.

News

Stay updated on Seven Eight Capital, LP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email